496 related articles for article (PubMed ID: 23033854)
1. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcus neoformans isolates from Yaoundé human immunodeficiency virus-infected patients exhibited intra-individual genetic diversity and variation in antifungal susceptibility profiles between isolates from the same patient.
Kammalac Ngouana T; Drakulovski P; Krasteva D; Kouanfack C; Reynes J; Delaporte E; Boyom FF; Mallié M; Bertout S
J Med Microbiol; 2016 Jul; 65(7):579-589. PubMed ID: 27100672
[TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology reveals genetic diversity among 363 isolates of the Cryptococcus neoformans and Cryptococcus gattii species complex in 61 Ivorian HIV-positive patients.
Kassi FK; Drakulovski P; Bellet V; Krasteva D; Gatchitch F; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Mallié M; Menan HIE; Bertout S
Mycoses; 2016 Dec; 59(12):811-817. PubMed ID: 27461533
[TBL] [Abstract][Full Text] [Related]
4. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
[TBL] [Abstract][Full Text] [Related]
5. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
Liaw SJ; Wu HC; Hsueh PR
Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis.
Illnait-Zaragozí MT; Martínez-Machín GF; Fernández-Andreu CM; Hagen F; Boekhout T; Klaassen CH; Meis JF
BMC Infect Dis; 2010 Oct; 10():289. PubMed ID: 20920321
[TBL] [Abstract][Full Text] [Related]
7. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
[TBL] [Abstract][Full Text] [Related]
8. Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole.
Kammalac Ngouana T; Dongtsa J; Kouanfack C; Tonfack C; Fomena S; Mallié M; Delaporte E; Boyom FF; Bertout S
J Mycol Med; 2015 Mar; 25(1):11-6. PubMed ID: 25467817
[TBL] [Abstract][Full Text] [Related]
9. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
Souza LK; Souza Junior AH; Costa CR; Faganello J; Vainstein MH; Chagas AL; Souza AC; Silva MR
Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
[TBL] [Abstract][Full Text] [Related]
10. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
11. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia.
Mlinarić-Missoni E; Hagen F; Chew WHM; Važić-Babić V; Boekhout T; Begovac J
J Med Microbiol; 2011 Oct; 60(Pt 10):1487-1495. PubMed ID: 21617022
[TBL] [Abstract][Full Text] [Related]
13. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ;
FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
[TBL] [Abstract][Full Text] [Related]
14. Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
Kassi FK; Drakulovski P; Bellet V; Roger F; Chabrol A; Krasteva D; Doumbia A; Landman R; Kakou A; Reynes J; Delaporte E; Menan HEI; Bertout S
PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007812. PubMed ID: 31738768
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru.
Bejar V; Tello M; García R; Guevara JM; Gonzales S; Vergaray G; Valencia E; Abanto E; Ortega-Loayza AG; Hagen F; Gutierrez EL
Rev Iberoam Micol; 2015; 32(2):88-92. PubMed ID: 25556051
[TBL] [Abstract][Full Text] [Related]
16. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
[TBL] [Abstract][Full Text] [Related]
17. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
Nyazika TK; Herkert PF; Hagen F; Mateveke K; Robertson VJ; Meis JF
Diagn Microbiol Infect Dis; 2016 Nov; 86(3):289-292. PubMed ID: 27608538
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
20. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
